Trust · Vetting a provider

Is online sermorelin legitimate?

Q: Is it legitimate to get sermorelin online?

It can be, and the way to tell is procedural rather than aesthetic. A legitimate path involves a licensed physician who evaluates you and is able to decline, a compounding pharmacy licensed in the United States, a prescription written in your name, and measurement available before and after. A path missing any of those is offering something different, however professional the site looks.

Q: What is the single best question to ask?

Ask what happens when a lab result or a history finding argues against therapy. A provider whose process can only end in a prescription has no answer to that question. At Kesbury Health the physician review can end the conversation, and so can the optional Longevity Lab Panel when it is run. That is what the step is for.

Q: Is compounded sermorelin FDA-approved?

No. Compounded sermorelin is not an FDA-approved finished drug product. It is compounded on the basis that sermorelin is the active ingredient of a previously approved drug. A provider that describes compounded medication as FDA-approved is misdescribing the category.

Q: What about research-use-only peptides sold online?

Those are not medications dispensed for human use. They are not prepared under pharmacy standards, they come with no prescriber who knows your history, and they come with no measurement. The lower price reflects the smaller thing being purchased.

Q: How do I verify a certification?

Check it at the certifying body rather than believing a badge image. LegitScript publishes a per-domain certification status page, and Kesbury Health's is linked from the seal on this site. A seal graphic on its own is a picture.

A sermorelin-specific version of the vetting checklist: what to verify before you pay, and the one question whose answer separates a clinical process from a fulfilment pipeline.

Medically reviewed by the Kesbury Health physician · Last updated 2026-10-07

Quick answer

Getting sermorelin online can be legitimate, and whether it is depends on four things you can check before you pay: a licensed physician who evaluates you and is able to decline, a pharmacy licensed in the United States doing the compounding, a prescription written in your name, and measurement available before and after. Sermorelin has a real research record going back decades, including controlled human studies in older adults [1][2] and a review of its use in pediatric growth hormone deficiency [3]. That record is what distinguishes it from peptides that circulate online without one. It does not make any particular seller legitimate. Compounded sermorelin is not an FDA-approved finished drug product, and a provider describing it as approved is misdescribing the category. This is the sermorelin-specific companion to the general telehealth vetting checklist on this site.

The four things that make an online sermorelin path legitimate

1. A licensed physician who can say no

The clinical layer has to be able to decline, not merely to authorise. The way to test it is to ask what happens when a lab result or a history finding argues against therapy. At Kesbury Health the physician review can decline, and when the optional $129 Longevity Lab Panel is run, if the results identify a concern, the physician may stop, change, or further evaluate therapy.

2. A U.S. licensed compounding pharmacy

Compounded sermorelin should be prepared by a licensed compounding pharmacy against a prescription written for you. That is a different supply chain from a research-use-only vial bought online, which is not prepared for human use and is not dispensed under pharmacy standards.

3. A prescription written for you

Patient-specific compounding is for an individual patient. A protocol identical for everyone who buys it is not that, whatever the checkout page says.

4. Measurement, before and after

IGF-1 is the practical marker of growth hormone axis activity, because growth hormone is released in pulses and a random measurement of it is close to uninformative. Endocrine Society guidance describes titration against clinical response and IGF-1 rather than a fixed schedule [4], and a 2011 consensus statement addressed how much IGF-1 assays vary between laboratories [5]. Measurement without a baseline to compare against is decoration.

Signals that should make you slow down

None of these is a certainty of bad practice, and any one of them is a reason to ask a harder question.

A provider that promises a specific result by a specific date is not describing medicine, because outcomes are not promised in medicine.
A site that describes a compounded medication as FDA-approved is not describing the category correctly.
A process with no laboratory step, or one whose laboratory step cannot change the outcome, is not measuring anything.
A checkout that completes before any clinician has seen your history has put the order ahead of the evaluation.
A seal graphic that does not link to a verifiable status page at the certifying body is a picture rather than a verification.
A price that appears only after you have entered payment details is not published pricing.
Before-and-after imagery and testimonial claims are not evidence of anything, and regulators treat unsubstantiated versions of them as a violation rather than as marketing.

What the sermorelin evidence base does and does not support

It supports the mechanism. A 1992 controlled study found that older men had lower growth hormone and IGF-1 than young men and that twice-daily GHRH(1-29) over 14 days reversed that difference [1]. A 1997 study had eleven healthy men aged 64 to 76 with low baseline IGF-1 self-inject nightly at home for six weeks [2]. A 1999 review described sustained increases in height velocity over 12 months of sermorelin treatment in children with growth hormone deficiency [3].

It also supports a measurable biochemical effect rather than a felt one: a 2012 controlled trial reported that GHRH treatment increased IGF-1 levels by 117% (P < .001) [6]. A laboratory marker moving is not the same as a person improving.

It does not support outcome promises in healthy adults. The studies are small, they are old, and they measured markers rather than how people felt over years. The honest position is that sermorelin may support sleep quality, recovery and body composition goals within a physician-directed plan, that individual results vary, and that anyone stating it more strongly is going past the evidence.

How to verify Kesbury Health specifically

LegitScript certification. Kesbury Health is LegitScript certified, #51875982, and the seal on this site links to the certification status page at LegitScript rather than to an image.
Published pricing. Sermorelin $149 for the first month, then $249 per month; NAD+ $149, then $299 per month; Longevity Stack (NAD+ and sermorelin together) $249, then $349 per month; Longevity Lab Panel $129 one time (optional). All shown before checkout.
Stated licensure. Ten states, listed by name on this site, with eligibility confirmed during the assessment.
A lab step that means something. The Longevity Lab Panel is optional, and when it is run its results go to the physician and can change the outcome, not just decorate it.
A clinical team byline on these articles rather than an anonymous one.

How physician-directed sermorelin works at Kesbury Health

Complete a short online assessment about your goals, symptoms and health history. It takes about 60 seconds to begin.
A licensed Kesbury Health physician reviews what you submitted and decides whether therapy is a reasonable fit for you, or whether something else should be looked at first.
Optional baseline labs. The $129 Longevity Lab Panel is optional. If you add it, it is ordered after approval and gives your physician a baseline for monitoring and, when appropriate, later dose adjustments. You can skip it now and add it later. If the results show a reason to stop, change, or further evaluate therapy, your physician will let you know. When it is run, the results can still end the conversation rather than continue it.
If therapy is appropriate, the medication is compounded by a licensed U.S. pharmacy and shipped to your door, with dosing set to you rather than to a chart.
Ongoing physician oversight follows the protocol set at approval: a check-in questionnaire about every 30 days and a physician reassessment about every 90 days determine whether treatment continues or changes.

Care is delivered by telehealth to residents of the ten states where your Kesbury Health physician is licensed: Alabama, District of Columbia, Delaware, Florida, Maryland, Michigan, New Jersey, Ohio, Pennsylvania and Texas. Eligibility is confirmed during the assessment.

Frequently asked questions

Is it legitimate to get sermorelin online?

It can be, and the way to tell is procedural rather than aesthetic. A legitimate path involves a licensed physician who evaluates you and is able to decline, a compounding pharmacy licensed in the United States, a prescription written in your name, and measurement available before and after. A path missing any of those is offering something different, however professional the site looks.

What is the single best question to ask?

Ask what happens when a lab result or a history finding argues against therapy. A provider whose process can only end in a prescription has no answer to that question. At Kesbury Health the physician review can end the conversation, and so can the optional Longevity Lab Panel when it is run. That is what the step is for.

Is compounded sermorelin FDA-approved?

No. Compounded sermorelin is not an FDA-approved finished drug product. It is compounded on the basis that sermorelin is the active ingredient of a previously approved drug. A provider that describes compounded medication as FDA-approved is misdescribing the category.

What about research-use-only peptides sold online?

Those are not medications dispensed for human use. They are not prepared under pharmacy standards, they come with no prescriber who knows your history, and they come with no measurement. The lower price reflects the smaller thing being purchased.

How do I verify a certification?

Check it at the certifying body rather than believing a badge image. LegitScript publishes a per-domain certification status page, and Kesbury Health's is linked from the seal on this site. A seal graphic on its own is a picture.

Vet us with the same checklist

Start the Kesbury Health evaluation. Ask what happens if the Longevity Lab Panel argues against therapy, and note that the answer here is that sermorelin is not prescribed.

Start your evaluation →

Kesbury Health is a LegitScript-certified (#51875982) telehealth longevity practice licensed in ten states. Sermorelin and NAD+ are compounded medications prescribed by a licensed physician after review. Compounded medications are not FDA-approved. This page is educational and is not individualized medical advice. Statements on this page have not been evaluated by the FDA. Individual results vary.

References (primary sources)

Every reference below was checked against its PubMed record on 2026-09-02. Links open the abstract.

Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. 1992;75(2):530-535. doi:10.1210/jcem.75.2.1379256. PMID 1379256.
Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. doi:10.1016/s0026-0495(97)90174-8. PMID 9005976.
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007. PMID 18031173.
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2011;96(6):1587-1609. doi:10.1210/jc.2011-0179. PMID 21602453.
Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry. 2011;57(4):555-559. doi:10.1373/clinchem.2010.150631. PMID 21285256.
Baker LD, Barsness SM, Borson S, Merriam GR, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 2012;69(11):1420-1429. doi:10.1001/archneurol.2012.1970. PMID 22869065.

Keep reading